0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Metyrapone Inhibition of 3H-Hydrocortisone Uptake and Binding in Various Brain Regions of the Pig

      , ,

      Neuroendocrinology

      S. Karger AG

      Binding, Metyrapone, Hydrocortisone, Brain

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Metyrapone (MET) inhibition of hydrocortisone (<sup>3</sup>H-HC) uptake and binding in the cytosol and nucleus of various brain regions of the pig was demonstrated in vivo. The hippocampus, hypothalamus and septum were the regions most sensitive to the inhibition by MET. The hippocampus exhibited the greatest reduction in <sup>3</sup>H-HC concentration in whole homogenate, bound in cytosol and in nuclei. The anterior pituitary and cerebral cortex were the least sensitive to MET. In vitro incubation of hypothalami with <sup>3</sup>H-HC and MET substantiated the results obtained in vivo with regard to the inhibitory action of MET on <sup>3</sup>H-HC uptake and binding. These results were interpreted to indicate that MET may act directly in certain brain regions and that this inhibitory action has important implications for both experimental and clinical uses of this drug.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1976
          1976
          25 March 2008
          : 22
          : 2
          : 183-192
          Affiliations
          University of Oklahoma Health Sciences Center, Department of Physiology and Biophysics. Oklahoma City, Okla.
          Article
          122625 Neuroendocrinology 1976;22:183–192
          10.1159/000122625
          1028948
          © 1976 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10
          Categories
          Paper

          Comments

          Comment on this article